Innocutis Announces Three New Prescribing Options for BIONECT™
CHARLESTON, S.C., Sept. 18, 2012 /PRNewswire/ -- Innocutis is pleased to announce the introduction of three new prescribing options of Bionect® (hyaluronic acid sodium salt, 0.2%): an aqueous base 20ml spray, and aqueous base 100g cream and gel formulations.
Available by prescription only, Bionect is formulated using a patented low molecular weight hyaluronic acid (LMWHA) and is indicated for irritations of the skin and managing redness associated with chronic conditions.
Market research has shown that patients and physicians are looking for value options when treating chronic conditions. The new Bionect 100g aqueous gel and cream formulations double the current treatment size options and are preferred by patients treating large skin areas affected by irritation and redness.
While creams and gels are commonly prescribed for topical use, they are not ideal for all areas of the body. Bionect spray 20ml is ideal for patients to use for symptoms occurring near the hairline or hair-bearing areas.
For more information or help locating a physician near you to prescribe Bionect, please visit http://bionect.com/physician-finder/
Innocutis is a pharmaceutical and medical device company specializing in the development and commercialization of therapies focused on medical treatments of dermatological conditions. We believe our focus on dermatologic conditions sets us apart as a company that understands the growing needs of the dermatology specialty. Our commitment is to be best-in-class in skin-related therapies, providing clinicians with improved solutions for the management of daily challenges experienced in their practice.
Vice President of Sales & Marketing
This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.